Form 8-K - Current report:
SEC Accession No. 0001558370-23-015422
Filing Date
2023-09-05
Accepted
2023-09-05 07:39:11
Documents
16
Period of Report
2023-09-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K olma-20230905x8k.htm   iXBRL 8-K 53949
2 EX-10.1 olma-20230905xex10d1.htm EX-10.1 220183
3 EX-10.2 olma-20230905xex10d2.htm EX-10.2 456127
4 EX-99.1 olma-20230905xex99d1.htm EX-99.1 20920
5 GRAPHIC olma-20230905xex99d1001.jpg GRAPHIC 6685
  Complete submission text file 0001558370-23-015422.txt   1014991

Data Files

Seq Description Document Type Size
6 EX-101.SCH olma-20230905.xsd EX-101.SCH 3118
7 EX-101.LAB olma-20230905_lab.xml EX-101.LAB 15264
8 EX-101.PRE olma-20230905_pre.xml EX-101.PRE 9652
10 EXTRACTED XBRL INSTANCE DOCUMENT olma-20230905x8k_htm.xml XML 4635
Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39712 | Film No.: 231234147
SIC: 2834 Pharmaceutical Preparations